LMR Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-21,500
Closed -$9.6M – 1806
2026
Q1
$9.6M Buy
21,500
+16,500
+330% +$7.69M 0.02% 446
2025
Q4
$2.27M Hold
5,000
– – ﹤0.01% 779
2025
Q3
$1.96M Buy
+5,000
New +$2.09M 0.01% 739
2025
Q1
– Sell
-145,200
Closed -$58.5M – 1653
2024
Q4
$58.5M Buy
+145,200
New +$67.3M 0.49% 28
2024
Q1
– Sell
-57,800
Closed -$23.5M – 1326
2023
Q4
$23.5M Buy
+57,800
New +$21.4M 0.27% 89

Other funds holding VRTX

LMR Partners's VRTX Position: Q3 2026 in Review

LMR Partners increased its Vertex Pharmaceuticals (VRTX) stake by 69% in Q3 2026, buying an estimated $3.51M and bringing the position to 16,823 shares worth $8.8M. The position accounts for 0.03% of the portfolio, ranked #507.

LMR Partners first reported a position in VRTX in Q4 2014 and has held it in 33 quarters since. The position peaked at $37.8M in Q4 2024. 1,797 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • LMR Partners held 16,823 shares of Vertex Pharmaceuticals worth $8.8M as of Q3 2026.
  • LMR Partners bought 6,861 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.51M.
  • Vertex Pharmaceuticals made up 0.03% of LMR Partners's portfolio in Q3 2026, its #507 holding.
  • LMR Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 33 quarters since.
  • LMR Partners's Vertex Pharmaceuticals position peaked at $37.8M in Q4 2024.
  • 1,797 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.